Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 263

1.

Early viral suppression improves neurocognitive outcomes in HIV-infected children.

Crowell CS, Huo Y, Tassiopoulos K, Malee KM, Yogev R, Hazra R, Rutstein RM, Nichols SL, Smith RA, Williams PL, Oleske J, Muller WJ; PACTG 219C Study Team and the Pediatric HIVAIDS Cohort Study (PHACS).

AIDS. 2015 Jan 28;29(3):295-304. doi: 10.1097/QAD.0000000000000528.

2.

Dramatic decline in substance use by HIV-infected pregnant women in the United States from 1990 to 2012.

Rough K, Tassiopoulos K, Kacanek D, Griner R, Yogev R, Rich KC, Seage GR 3rd; Pediatric HIVAIDS Cohort Study.

AIDS. 2015 Jan 2;29(1):117-23. doi: 10.1097/QAD.0000000000000503.

PMID:
25562496
3.

Serum palivizumab level is associated with decreased severity of respiratory syncytial virus disease in high-risk infants.

Forbes ML, Kumar VR, Yogev R, Wu X, Robbie GJ, Ambrose CS.

Hum Vaccin Immunother. 2014;10(10):2789-94. doi: 10.4161/hv.29635.

PMID:
25483663
4.

Clinical characteristics and genotypes of rotavirus in adults.

Anderson EJ, Shippee DB, Tate JE, Larkin B, Bregger MD, Katz BZ, Noskin GA, Sederdahl BK, Shane AL, Parashar UD, Yogev R.

J Infect. 2014 Dec 4. pii: S0163-4453(14)00371-5. doi: 10.1016/j.jinf.2014.11.012. [Epub ahead of print] No abstract available.

PMID:
25481405
5.

Multicenter clinical evaluation of the novel Alere™ i Influenza A&B isothermal nucleic acid amplification test.

Bell J, Bonner A, Cohen DM, Birkhahn R, Yogev R, Triner W, Cohen J, Palavecino E, Selvarangan R.

J Clin Virol. 2014 Sep;61(1):81-6. doi: 10.1016/j.jcv.2014.06.001. Epub 2014 Jun 7.

6.

Use of opportunistic clinical data and a population pharmacokinetic model to support dosing of clindamycin for premature infants to adolescents.

Gonzalez D, Melloni C, Yogev R, Poindexter BB, Mendley SR, Delmore P, Sullivan JE, Autmizguine J, Lewandowski A, Harper B, Watt KM, Lewis KC, Capparelli EV, Benjamin DK Jr, Cohen-Wolkowiez M; Best Pharmaceuticals for Children Act – Pediatric Trials Network Administrative Core Committee.

Clin Pharmacol Ther. 2014 Oct;96(4):429-37. doi: 10.1038/clpt.2014.134. Epub 2014 Jun 20.

PMID:
24949994
7.

Neurologic disease in HIV-infected children and the impact of combination antiretroviral therapy.

Crowell CS, Malee KM, Yogev R, Muller WJ.

Rev Med Virol. 2014 Sep;24(5):316-31. doi: 10.1002/rmv.1793. Epub 2014 May 8.

PMID:
24806816
8.

Long-term highly suppressed HIV-infected children and adolescents with negative rapid HIV tests due to significant antibody loss.

Merchant M, Wright M, Kabat W, Yogev R.

J Clin Virol. 2014 Mar;59(3):172-6. doi: 10.1016/j.jcv.2013.11.012. Epub 2013 Dec 5.

PMID:
24440176
9.

Improved access to early infant diagnosis is a critical part of a child-centric prevention of mother-to-child transmission agenda.

Ghadrshenas A, Ben Amor Y, Chang J, Dale H, Sherman G, Vojnov L, Young P, Yogev R; Child Survival Working Group of the Interagency Task Team on the Prevention and Treatment of HIV infection in Pregnant Women, Mothers and Children.

AIDS. 2013 Nov;27 Suppl 2:S197-205. doi: 10.1097/QAD.0000000000000104. Review.

PMID:
24361629
10.

Addressing and improving the continuum of care for HIV-affected children: challenges and solutions.

Kellerman SE, Sugandhi N, Luo C, McClure C, Yogev R.

AIDS. 2013 Nov;27 Suppl 2:S135-7. doi: 10.1097/QAD.0000000000000129. No abstract available.

PMID:
24361622
11.

Safety and immunogenicity of a live attenuated RSV vaccine in healthy RSV-seronegative children 5 to 24 months of age.

Malkin E, Yogev R, Abughali N, Sliman J, Wang CK, Zuo F, Yang CF, Eickhoff M, Esser MT, Tang RS, Dubovsky F.

PLoS One. 2013 Oct 29;8(10):e77104. doi: 10.1371/journal.pone.0077104. eCollection 2013.

12.

Safety and infectivity of two doses of live-attenuated recombinant cold-passaged human parainfluenza type 3 virus vaccine rHPIV3cp45 in HPIV3-seronegative young children.

Englund JA, Karron RA, Cunningham CK, Larussa P, Melvin A, Yogev R, Handelsman E, Siberry GK, Thumar B, Schappell E, Bull CV, Chu HY, Schaap-Nutt A, Buchholz U, Collins PL, Schmidt AC; International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) P1096 Study Group.

Vaccine. 2013 Nov 19;31(48):5706-12. doi: 10.1016/j.vaccine.2013.09.046. Epub 2013 Oct 5.

13.

Indirect protection of adults from rotavirus by pediatric rotavirus vaccination.

Anderson EJ, Shippee DB, Weinrobe MH, Davila MD, Katz BZ, Reddy S, Cuyugan MG, Lee SY, Simons YM, Yogev R, Noskin GA.

Clin Infect Dis. 2013 Mar;56(6):755-60. doi: 10.1093/cid/cis1010. Epub 2013 Jan 23.

14.

The glory of guidelines and the twilight of reality: controversies and challenges in the prevention and treatment of HIV in children.

Anderson EJ, Yogev R.

Expert Rev Anti Infect Ther. 2012 Jul;10(7):761-74. doi: 10.1586/eri.12.60. Review.

PMID:
22943400
15.

Safety and immunogenicity of 2009 pandemic H1N1 influenza vaccination in perinatally HIV-1-infected children, adolescents, and young adults.

Flynn PM, Nachman S, Muresan P, Fenton T, Spector SA, Cunningham CK, Pass R, Yogev R, Burchett S, Heckman B, Bloom A, Utech LJ, Anthony P, Petzold E, Levy W, Siberry GK, Ebiasah R, Miller J, Handelsman E, Weinberg A; IMPAACT P1088 Team.

J Infect Dis. 2012 Aug 1;206(3):421-30. doi: 10.1093/infdis/jis360. Epub 2012 May 21. Erratum in: J Infect Dis. 2012 Dec 15;206(12):1951.

16.

Dynamics of the resting CD4(+) T-cell latent HIV reservoir in infants initiating HAART less than 6 months of age.

Persaud D, Palumbo PE, Ziemniak C, Hughes MD, Alvero CG, Luzuriaga K, Yogev R, Capparelli EV, Chadwick EG.

AIDS. 2012 Jul 31;26(12):1483-90. doi: 10.1097/QAD.0b013e3283553638.

17.

Residential crowding and severe respiratory syncytial virus disease among infants and young children: a systematic literature review.

Colosia AD, Masaquel A, Hall CB, Barrett AM, Mahadevia PJ, Yogev R.

BMC Infect Dis. 2012 Apr 20;12:95. doi: 10.1186/1471-2334-12-95. Review.

18.

Developments in imaging: 'a huge difference in primary care'.

Donaldson JS, Yogev R, Shulman ST, Selva TJ, Gersony WM, Steinhorn RH, Block SL.

Pediatr Ann. 2012 Mar;41(3):122-3. doi: 10.3928/00904481-20120206-13. No abstract available.

PMID:
22420386
19.

Pediatric oncology: "an area of great change".

Shulman ST, Murphy SB, Yogev R.

Pediatr Ann. 2012 Feb;41(2):79-80. doi: 10.3928/00904481-20120110-12. No abstract available.

PMID:
22300185
20.

Assessment of lopinavir pharmacokinetics with respect to developmental changes in infants and the impact on weight band-based dosing.

Nikanjam M, Chadwick EG, Robbins B, Alvero C, Palumbo P, Yogev R, Pinto J, Hazra R, Hughes ML, Heckman BE, Capparelli EV; IMPAACT P1030 Team.

Clin Pharmacol Ther. 2012 Feb;91(2):243-9. doi: 10.1038/clpt.2011.218. Epub 2011 Dec 21.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk